Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 58

1.

Medical and Behavioral Approaches to Engage People Who Inject Drugs Into Care for Hepatitis C Virus Infection.

Gonzalez SA, Fierer DS, Talal AH.

Addict Disord Their Treat. 2017 Jun;16(2 Suppl 1):S1-S23. doi: 10.1097/ADT.0000000000000104. Epub 2017 May 17.

2.

The Interaction of Risk Network Structures and Virus Natural History in the Non-spreading of HIV Among People Who Inject Drugs in the Early Stages of the Epidemic.

Dombrowski K, Khan B, Habecker P, Hagan H, Friedman SR, Saad M.

AIDS Behav. 2017 Apr;21(4):1004-1015. doi: 10.1007/s10461-016-1568-6.

PMID:
27699596
3.

Harm reduction interventions in HIV care: a qualitative exploration of patient and provider perspectives.

Carlberg-Racich S.

PeerJ. 2016 Apr 14;4:e1932. doi: 10.7717/peerj.1932. eCollection 2016.

4.

The spread of hepatitis C virus genotype 1a in North America: a retrospective phylogenetic study.

Joy JB, McCloskey RM, Nguyen T, Liang RH, Khudyakov Y, Olmstead A, Krajden M, Ward JW, Harrigan PR, Montaner JS, Poon AF.

Lancet Infect Dis. 2016 Jun;16(6):698-702. doi: 10.1016/S1473-3099(16)00124-9. Epub 2016 Mar 30.

5.

Prevalence of hepatitis C virus infection among HIV+ men who have sex with men: a systematic review and meta-analysis.

Jordan AE, Perlman DC, Neurer J, Smith DJ, Des Jarlais DC, Hagan H.

Int J STD AIDS. 2017 Feb;28(2):145-159. doi: 10.1177/0956462416630910. Epub 2016 Jul 10. Review.

PMID:
26826159
6.

Sex work and HIV incidence among people who inject drugs.

Kerr T, Shannon K, Ti L, Strathdee S, Hayashi K, Nguyen P, Montaner J, Wood E.

AIDS. 2016 Feb 20;30(4):627-34. doi: 10.1097/QAD.0000000000000948.

7.

Can HIV and Hepatitis C Virus Infection be Eliminated Among Persons Who Inject Drugs?

Perlman DC, Des Jarlais DC, Feelemyer J.

J Addict Dis. 2015;34(2-3):198-205. doi: 10.1080/10550887.2015.1059111.

8.

Incidence and prevalence of hepatitis c virus infection among persons who inject drugs in New York City: 2006-2013.

Jordan AE, Des Jarlais DC, Arasteh K, McKnight C, Nash D, Perlman DC.

Drug Alcohol Depend. 2015 Jul 1;152:194-200. doi: 10.1016/j.drugalcdep.2015.03.039. Epub 2015 Apr 13.

9.

Hepatitis C viremia patterns in incident hepatitis C infection and one year later in 150 prospectively tested persons who inject drugs.

Alanko Blomé M, Björkman P, Molnegren V, Höglund P, Widell A.

PLoS One. 2014 May 15;9(5):e97022. doi: 10.1371/journal.pone.0097022. eCollection 2014.

10.

Integrating health and prevention services in syringe access programs: a strategy to address unmet needs in a high-risk population.

Burr CK, Storm DS, Hoyt MJ, Dutton L, Berezny L, Allread V, Paul S.

Public Health Rep. 2014 Jan-Feb;129 Suppl 1:26-32.

11.

Hepatitis C virus maintains infectivity for weeks after drying on inanimate surfaces at room temperature: implications for risks of transmission.

Paintsil E, Binka M, Patel A, Lindenbach BD, Heimer R.

J Infect Dis. 2014 Apr 15;209(8):1205-11. doi: 10.1093/infdis/jit648. Epub 2013 Nov 23.

12.

Combined HIV prevention, the New York City condom distribution program, and the evolution of safer sex behavior among persons who inject drugs in New York City.

Des Jarlais DC, Arasteh K, McKnight C, Feelemyer J, Hagan H, Cooper HL, Perlman DC.

AIDS Behav. 2014 Mar;18(3):443-51. doi: 10.1007/s10461-013-0664-0.

13.

Prevalence of HIV infection and risk behaviors among younger and older injecting drug users in the United States, 2009.

Broz D, Pham H, Spiller M, Wejnert C, Le B, Neaigus A, Paz-Bailey G.

AIDS Behav. 2014 Apr;18 Suppl 3:284-96. doi: 10.1007/s10461-013-0660-4.

14.

Hepatitis C infection in non-treatment-seeking heroin users: the burden of cocaine injection.

Roux P, Fugon L, Jones JD, Comer SD.

Am J Addict. 2013 Nov-Dec;22(6):613-8. doi: 10.1111/j.1521-0391.2013.12058.x. Epub 2013 Jun 6.

15.

Prevalence of HCV infection among clients in community-based health settings in Hawaii, 2002-2010: assessing risk factors.

Porter JC, Lusk HM, Katz AR.

Am J Public Health. 2014 Aug;104(8):1534-9. doi: 10.2105/AJPH.2013.301282. Epub 2013 Sep 12.

16.

High coverage needle/syringe programs for people who inject drugs in low and middle income countries: a systematic review.

Des Jarlais DC, Feelemyer JP, Modi SN, Abdul-Quader A, Hagan H.

BMC Public Health. 2013 Jan 19;13:53. doi: 10.1186/1471-2458-13-53. Review.

17.

Peer-education intervention to reduce injection risk behaviors benefits high-risk young injection drug users: a latent transition analysis of the CIDUS 3/DUIT study.

Mackesy-Amiti ME, Finnegan L, Ouellet LJ, Golub ET, Hagan H, Hudson SM, Latka MH, Garfein RS.

AIDS Behav. 2013 Jul;17(6):2075-83. doi: 10.1007/s10461-012-0373-0.

18.

A simple strategy to identify acute hepatitis C virus infection among newly incarcerated injection drug users.

Kim AY, Nagami EH, Birch CE, Bowen MJ, Lauer GM, McGovern BH.

Hepatology. 2013 Mar;57(3):944-52. doi: 10.1002/hep.26113. Epub 2013 Feb 15.

19.

Hepatitis C viremia and genotype distribution among a sample of nonmedical prescription drug users exposed to HCV in rural Appalachia.

Young AM, Crosby RA, Oser CB, Leukefeld CG, Stephens DB, Havens JR.

J Med Virol. 2012 Sep;84(9):1376-87. doi: 10.1002/jmv.23252.

20.

Injecting risk behavior among traveling young injection drug users: travel partner and city characteristics.

Montgomery ME, Fatch RS, Evans JL, Yu M, Davidson PJ, Page K, Hahn JA.

J Urban Health. 2013 Jun;90(3):500-15. doi: 10.1007/s11524-012-9718-2.

Supplemental Content

Support Center